Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 2/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 2/20 | 0.43 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 3/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | MMP3 | P08254 | 3/20 | 0.41 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7864065 | 1.00 | MMP2 (0.54) | MMP2HDAC8CTBP2MMP13MMP12 | |
| SCHEMBL6931485 | 0.84 | MLYCD (0.53) | LMNARAB9ASMN1; SMN2 | |
| SCHEMBL6931486 | 0.84 | MLYCD (0.53) | LMNARAB9ASMN1; SMN2 | |
| SCHEMBL7442828 | 0.83 | MMP2 (0.41) | MMP2CTBP2MAP4K4 | |
| SCHEMBL7442833 | 0.83 | MMP2 (0.41) | MMP2CTBP2MAP4K4 | |
| SCHEMBL7862874 | 0.81 | SMN1; SMN2 (0.66) | MMP2MMP13MMP12GSK3BFFAR1 | |
| SCHEMBL7448552 | 0.80 | MMP2 (0.46) | MMP2CTBP2MMP13MMP12GSK3B | |
| SCHEMBL7448546 | 0.80 | MMP2 (0.46) | MMP2CTBP2MMP13MMP12GSK3B | |
| SCHEMBL7764807 | 0.80 | KMT2A (0.56) | HDAC8CTBP2FFAR1LMNACYP1A2 | |
| SCHEMBL4426383 | 0.80 | HDAC8 (0.48) | HDAC8CTBP2FFAR1LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | claimed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | claimed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | claimed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | claimed |
| US-6307089-B2 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | disclosed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP26, MMP1, MMP9 | MMP2 4/4885HDAC8 878/4885CTBP2 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.